Translation and validation

Biotechnology Innovation Organization, Informa Pharma Intelligence, Quantitative Life Sciences. Clinical Development Success Rates and Contributing Factors 2011-2020.; 2021:34. https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf.

Hubert Dirven, Gunn E. Vist, Sricharan Bandhakavi, et al. Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. Scientific Reports. 2021;11(1):6403. doi:10.1038/s41598-021-85708-2

Rachel L. C. Barrett, Matthew Dawson, Tim B. Dyrby, et al. Differences in Frontal Network Anatomy Across Primate Species. Journal of Neuroscience. 2020;40(10):2094-2107. doi:10.1523/JNEUROSCI.1650-18.2019

Michael M. Webster, Christian Rutz. How STRANGE are your study animals? Nature. 2020;582:337-340. doi:10.1038/d41586-020-01751-5

Donald E. Ingber. Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? Advanced Science. 2020;7(22):2002030. doi:10.1002/advs.202002030

S. Vincent Rajkumar. The high cost of prescription drugs: causes and solutions. Blood Cancer Journal. 2020;10(6):71. doi:10.1038/s41408-020-0338-x

Olivier J. Wouters, Martin McKee, Jeroen Luyten. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166

Stanley T. Parish, Michael Aschner, Warren Casey, et al. An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regulatory Toxicology and Pharmacology. 2020;112:104592. doi:10.1016/j.yrtph.2020.104592

Pandora Pound, Merel Ritskes-Hoitinga. Can prospective systematic reviews of animal studies improve clinical translation? Journal of Translational Medicine. 2020;18:15. doi:10.1186/s12967-019-02205-x

Antje Schmidt-Pogoda, Nadine Bonberg, Mailin Hannah Marie Koecke, et al. Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents. Annals of Neurology. 2020;87(1):40-51. doi:10.1002/ana.25643